{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:03:53Z","timestamp":1789524233807,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01939-x","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:56:01Z","timestamp":1789523761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deeper delving Nav1.8 inhibitor Suzetrigine in chronic pain"],"prefix":"10.1038","author":[{"given":"Yu-Feng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1939_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/j.pain.0000000000003425","volume":"166","author":"J Yang","year":"2025","unstructured":"Yang J, Xie YF, Smith R, Ratte S, Prescott SA. Discordance between preclinical and clinical testing of Na V 1.7-selective inhibitors for pain. Pain. 2025;166:481\u2013501.","journal-title":"Pain"},{"key":"1939_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/biom15050694","volume":"15","author":"YF Xie","year":"2025","unstructured":"Xie YF. Nav1.8 and chronic pain: from laboratory animals to cliniCAL PATIEnts. Biomolecules. 2025;15:694.","journal-title":"Biomolecules"},{"key":"1939_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/j.pain.0000000000003931","volume":"167","author":"ML Uhelski","year":"2026","unstructured":"Uhelski ML, Schaub MK, Espinosa F, Heles M, Cortes N, Li Y, et al. Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons with differential pain etiology. Pain. 2026;167:1430\u20139.","journal-title":"Pain"},{"key":"1939_CR4","doi-asserted-by":"crossref","unstructured":"Freeman R, Rauck R, Argoff C, Tian S, Miao X, Olivet H, et al. Suzetrigine, a selective pain signal inhibitor of NaV1.8 shows proof-of-concept for treatment of painful diabetic peripheral neuropathy (S11.002). Neurology. 2025;104(7 (Supp 1)):3054.","DOI":"10.1212\/WNL.0000000000210760"},{"key":"1939_CR5","doi-asserted-by":"publisher","first-page":"e2503570122","DOI":"10.1073\/pnas.2503570122","volume":"122","author":"RG Stewart","year":"2025","unstructured":"Stewart RG, Osorno T, Fujita A, Jo S, Ferraiuolo A, Carlin K, et al. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proc Natl Acad Sci USA. 2025;122:e2503570122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1939_CR6","doi-asserted-by":"publisher","first-page":"RP90960","DOI":"10.7554\/eLife.90960.3","volume":"12","author":"YF Xie","year":"2024","unstructured":"Xie YF, Yang J, Ratte S, Prescott SA. Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs. eLife. 2024;12:RP90960.","journal-title":"eLife"},{"key":"1939_CR7","doi-asserted-by":"publisher","first-page":"e0277262026","DOI":"10.1523\/JNEUROSCI.0277-26.2026","volume":"46","author":"YF Xie","year":"2026","unstructured":"Xie YF, Dedek C, Prescott SA. Quantifying changes in pain sensitivity using reproducible transcutaneous optogenetic stimulation in behaving mice. J Neurosci. 2026;46:e0277262026.","journal-title":"J Neurosci"},{"key":"1939_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-025-01253-3","volume":"18","author":"MY Ali","year":"2025","unstructured":"Ali MY, Antunes FTT, Huang S, Chen L, Zamponi GW. Pharmacological inhibition of NaV1.8 by suzetrigine reveals potent analgesic potential without tolerance development in mice. Mol Brain. 2025;18:86.","journal-title":"Mol Brain"},{"key":"1939_CR9","doi-asserted-by":"publisher","first-page":"e02114","DOI":"10.1213\/XAA.0000000000002114","volume":"19","author":"SR Nimma","year":"2025","unstructured":"Nimma SR, Kivanc TY, Colontonio MM. Use of Suzetrigine, a selective sodium channel blocker, in postoperative pain management for an adolescent patient with hereditary neuropathy: a case report. A&A Pract. 2025;19:e02114.","journal-title":"A&A Pract"},{"key":"1939_CR10","doi-asserted-by":"publisher","first-page":"162158","DOI":"10.52965\/001c.162158","volume":"18","author":"J Hasoon","year":"2026","unstructured":"Hasoon J, Nguyen A, Govindaraj R, Robinson CL. Suzetrigine for cancer-related bone pain: a three-patient case series. Orthop Rev. 2026;18:162158.","journal-title":"Orthop Rev"},{"key":"1939_CR11","doi-asserted-by":"publisher","first-page":"162149","DOI":"10.52965\/001c.162149","volume":"18","author":"S Joudeh","year":"2026","unstructured":"Joudeh S, Moore D, Hasoon J, Robinson CL, Idowu M, Oso T. Suzetrigine for vaso-occlusive pain in sickle cell disease: a three-patient case series. Orthop Rev. 2026;18:162149.","journal-title":"Orthop Rev"},{"key":"1939_CR12","doi-asserted-by":"publisher","first-page":"e2507342122","DOI":"10.1073\/pnas.2507342122","volume":"122","author":"DV Vasylyev","year":"2025","unstructured":"Vasylyev DV, Zhao P, Schulman BR, Waxman SG. Nav1.8: Intrinsic limits on the functional effect of abrogation in DRG neurons. Proc Natl Acad Sci USA. 2025;122:e2507342122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1939_CR13","doi-asserted-by":"publisher","first-page":"e202413596","DOI":"10.1085\/jgp.202413596","volume":"156","author":"DV Vasylyev","year":"2024","unstructured":"Vasylyev DV, Zhao P, Schulman BR, Waxman SG. Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain. J Gen Physiol. 2024;156:e202413596.","journal-title":"J Gen Physiol"},{"key":"1939_CR14","doi-asserted-by":"publisher","unstructured":"Palomino SM, Gabriel KA, Koduri A, Khan I, Syed AR, Horton P, et al. Nav1.8 mediates peripheral-to-central nociceptive transmission independently of central presynaptic mechanisms in human DRG-spinal cord circuits. BioRxiv [Preprint]. 2026. Available from: https:\/\/doi.org\/10.64898\/2026.02.27.708640.","DOI":"10.64898\/2026.02.27.708640"},{"key":"1939_CR15","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1523\/JNEUROSCI.23-26-08881.2003","volume":"23","author":"BC Hains","year":"2003","unstructured":"Hains BC, Klein JP, Saab CY, Craner MJ, Black JA, Waxman SG. Upregulation of sodium channel Nav 1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci. 2003;23:8881\u201392.","journal-title":"J Neurosci"},{"key":"1939_CR16","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1093\/brain\/awaf438","volume":"149","author":"CJ Zhang","year":"2026","unstructured":"Zhang CJ, Ji MJ, Zhou XL, Li S, Xu PF, Wu H, et al. Nav1.5 in the dorsal root ganglion plays a crucial role in mechanical hypersensitivity. Brain. 2026;149:2516\u201332.","journal-title":"Brain"},{"key":"1939_CR17","doi-asserted-by":"publisher","first-page":"918.","DOI":"10.3389\/fnins.2019.00918","volume":"13","author":"J Huang","year":"2019","unstructured":"Huang J, Estacion M, Zhao P, Dib-Hajj FB, Schulman B, Abicht A, et al. A novel gain-of-function Nav1.9 mutation in a child with episodic pain. Front Neurosci. 2019;13:918. https:\/\/doi.org\/10.3389\/fnins.2019.00918.","journal-title":"Front Neurosci"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01939-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:56:02Z","timestamp":1789523762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01939-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":17,"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01939-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}